Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
63.1 PLN | +4.30% | +0.16% | -29.89% |
May. 29 | Bioceltix S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 26 | Bioceltix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 28
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 42 | 18-08-12 | |
Andrij Wlach
DFI | Director of Finance/CFO | 40 | - |
Elzbieta Gocek
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jakub Grzesiak
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | - | - | |
Pawel Wielgus
PRN | Corporate Officer/Principal | 43 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,129,468 | 2,785,920 ( 67.46 %) | 0 | 67.46 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-29.89% | 62.62M | |
-10.90% | 80.24B | |
+20.00% | 8.84B | |
+23.62% | 3.66B | |
-2.92% | 3.2B | |
+17.57% | 1.78B | |
-0.39% | 1.31B | |
-27.76% | 1.2B | |
-30.02% | 1.17B | |
-22.42% | 1.01B |
- Stock Market
- Equities
- BCX Stock
- Company Bioceltix S.A.